Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment

Selvi, Nur; KAYMAZ, BURÇİN; Sahin, Handan; Pehlivan, Mustafa; Aktan, Cagdas; Dalmizrak, Aysegul; Inalpolat, Ezgi; KOSOVA, BUKET; YILMAZ, MEHMET; Okan, Vahap; Saydam, Guray

doi:10.1007/s11033-012-2207-6

Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment

Selvi N., KAYMAZ B., Sahin H. H., Pehlivan M., Aktan C., Dalmizrak A., ...Daha Fazla

MOLECULAR BIOLOGY REPORTS, cilt.40, sa.2, ss.1591-1597, 2013 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 40 Sayı: 2
Basım Tarihi: 2013
Doi Numarası: 10.1007/s11033-012-2207-6
Dergi Adı: MOLECULAR BIOLOGY REPORTS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1591-1597
Anahtar Kelimeler: Hes, Imatinib, Real-time PCR, FIP1L1-PDGFRA fusion
Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

The aim of this work was to report two cases of hypereosinophilic syndrome (HES). FIP1L1-PDGFRA fusion was assessed with two protocols at RNA level. The fusion transcript was found positive at the RNA level with both PCR methods in two cases. In this study, the efficiency of imatinib treatment and a dramatic response in two HES cases with multisystemic involvement showing the characteristics of a chronic myeloproliferative disease were presented. Both cases showed complete responses confirming that imatinib mesylate treatment could be successful even in patients with advanced HES having myeloproliferative disease.